ArticleCore evidence2019

Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy.

Maria Galkin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.